Liraglutide Cost in Hawaii 2026: Cash Price, Insurance, Medicaid, and Compounded Options

What Does Liraglutide Actually Cost in Hawaii Right Now?

Brand-name liraglutide carries a Novo Nordisk wholesale list price of $1,349 per month in 2026. Hawaii retail pharmacies average roughly $900 per month for cash-paying patients, reflecting standard dispenser markups and regional variation across Oahu, Maui, the Big Island, and Kauai. Compounded liraglutide from a licensed 503A pharmacy sits around $150 per month, making it the lowest-cost access point for most uninsured Hawaiians.

The gap between the $1,349 list price and the $900 average cash price reflects GoodRx-style pharmacy benefit manager (PBM) negotiation, coupon stacking, and competition among retail chains. CVS, Walgreens, Costco, and Longs Drug (a Hawaii regional staple) each price the drug differently on any given week. Running a GoodRx or RxSaver search before each fill can shave $50 to $150 off a single month's supply without insurance.

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA in 2010 under the brand Victoza for type 2 diabetes management and in 2014 under Saxenda for chronic weight management in adults with a body mass index (BMI) of 30 or higher, or BMI <27 with at least one weight-related comorbidity [1]. The drug stimulates insulin secretion in a glucose-dependent manner, slows gastric emptying, and reduces appetite signaling in the hypothalamus [2].

No FDA-approved generic liraglutide existed as of mid-2025. The original Victoza patent cluster does not expire until the late 2020s in some jurisdictions, so patients in Hawaii cannot yet walk into a pharmacy and request a generic substitution the way they might for metformin or lisinopril [3].

How Hawaii Medicaid (Med-QUEST) Handles Liraglutide Coverage

Hawaii Medicaid, administered through the Med-QUEST Division, does not cover liraglutide for either chronic weight management or type 2 diabetes as of the 2026 formulary cycle. This is a meaningful gap. Hawaii has an adult obesity prevalence of approximately 24.8% according to CDC Behavioral Risk Factor Surveillance System data [4], and type 2 diabetes affects an estimated 9.2% of Hawaii adults [5]. Both conditions are direct indications for liraglutide, yet the drug sits off-formulary for the roughly 380,000 Hawaiians enrolled in Med-QUEST.

The Endocrine Society's 2021 Clinical Practice Guideline on Pharmacological Management of Obesity states: "We recommend weight-loss pharmacotherapy as part of a comprehensive lifestyle intervention for patients with obesity or overweight with weight-related comorbidities, when benefits outweigh risks" [6]. Despite this guidance, state Medicaid programs retain broad discretion over formulary placement, and Hawaii has not added liraglutide to Med-QUEST covered medications.

Patients denied coverage can request a prior authorization (PA) appeal citing A1C levels, documented comorbidities, and failure of lifestyle interventions. PA approvals for off-formulary GLP-1 agents are granted in a minority of cases but do occur, particularly when prescribers document cardiovascular risk factors alongside the diabetes or obesity diagnosis. Contacting the Med-QUEST Ombudsman office at (808) 524-2036 is a practical first step for members who believe they have a strong clinical case [7].

For patients with both Medicaid and a secondary commercial plan (dual eligibility), the commercial plan may cover liraglutide and Medicaid can act as secondary payer for cost-sharing. This arrangement applies to some Hawaii residents enrolled in CHIP or through employer coverage while on Medicaid spend-down programs.

Is Compounded Liraglutide Legal in Hawaii?

Compounded liraglutide is legal in Hawaii when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription from a licensed prescriber [8]. Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies, requiring that compounds be made for individual patients, not manufactured in bulk for general distribution [9].

Hawaii's Department of Commerce and Consumer Affairs (DCCA) Pharmacy Program licenses and inspects 503A pharmacies operating within the state. Patients who receive compounded liraglutide from an out-of-state 503A pharmacy are also legally served provided that pharmacy holds a Hawaii non-resident pharmacy permit and the prescription originates from a licensed Hawaii prescriber or an appropriately licensed telehealth provider [10].

The FDA placed both semaglutide and tirzepatide on its drug shortage list in prior years, which opened a separate 503B outsourcing pathway for those drugs. Liraglutide has not appeared on the FDA shortage list in the same manner, which means 503B bulk compounding of liraglutide is generally not permitted. The legal pathway in Hawaii is therefore exclusively through 503A pharmacies filling individual prescriptions [9].

Quality differences between compounded and brand-name liraglutide are real. The FDA does not test or approve compounded formulations. A 2023 analysis published in JAMA raised concerns about variable peptide purity and concentration accuracy in compounded GLP-1 preparations [11]. Patients choosing compounded liraglutide should verify that the pharmacy holds current USP 797 and USP 800 certification and can provide a certificate of analysis (CoA) for each batch.

Compounded liraglutide pricing in Hawaii runs approximately $150 per month through compliant 503A pharmacies, compared to the $900 average retail cash price for Saxenda or Victoza. The savings are substantial, but they come with reduced regulatory oversight [11].

Which Insurance Plans Cover Liraglutide in Hawaii?

Coverage varies by plan type, employer, and the specific indication (diabetes vs. weight management). Victoza (liraglutide for type 2 diabetes) earns coverage more readily than Saxenda (liraglutide for obesity) across most Hawaiian commercial insurance products.

Hawaii's major commercial carriers include HMSA (the Hawaii Blue Cross Blue Shield affiliate), UnitedHealthcare Hawaii, Kaiser Permanente Hawaii, and AlohaCare. HMSA and UnitedHealthcare Hawaii plans that include a comprehensive pharmacy benefit generally place Victoza on Tier 3 (preferred brand) with a copay of $50 to $100 per month after deductible for employer-sponsored plans, though exact tier placement changes annually during formulary review cycles [12].

Saxenda faces steeper hurdles. Many Hawaii employer plans explicitly exclude weight-loss medications through a blanket exclusion rider, a practice permitted under ERISA for self-insured plans. Fully insured Hawaii plans are subject to Hawaii's insurance laws, but the state has not passed a mandate requiring obesity drug coverage equivalent to the pharmacy benefit mandates in some other states.

The Affordable Care Act (ACA) marketplace plans sold through Hawaii Health Connector cover prescription drugs as an essential health benefit, but formulary placement is plan-specific. A Bronze-tier ACA plan may exclude Saxenda entirely while a Gold-tier plan from the same insurer may cover it with a PA requirement. Checking the formulary drug search tool at HealthCare.gov before enrollment during open enrollment (November 1 to January 15) is the most reliable method to confirm liraglutide coverage before committing to a plan [13].

Medicare Part D plans cover Victoza for type 2 diabetes management when the prescriber documents inadequate glycemic control on metformin monotherapy or other first-line agents. Medicare currently does not cover weight-loss drugs, including Saxenda, under Part D; this exclusion stems from a statutory prohibition in the Medicare Modernization Act of 2003 that Congress has not yet overturned as of mid-2025 [14]. The Treat and Reduce Obesity Act, if passed, would change this, but it has not yet been enacted [15].

Novo Nordisk Patient Assistance and Savings Programs

Novo Nordisk operates two programs relevant to Hawaii patients. The My$99Insulin program does not apply to liraglutide, but the Victoza Savings Card and the Saxenda Savings Card can reduce out-of-pocket costs for commercially insured patients to as low as $25 per month for Victoza and $25 per month for Saxenda, subject to eligibility restrictions [16].

Eligibility criteria for the Novo Nordisk savings cards exclude patients whose primary coverage is a federal program: Medicare, Medicaid (including Hawaii Med-QUEST), TRICARE, or any other government-funded plan. Hawaii residents on Med-QUEST cannot use these cards. Uninsured patients also do not qualify for the standard savings card, though Novo Nordisk's Patient Assistance Program (PAP) provides free medication to uninsured patients whose household income falls at or below 400% of the federal poverty level [16].

To apply for the PAP, patients submit proof of income, a completed application signed by their prescriber, and documentation of insurance status to Novo Nordisk's patient services team. Processing typically takes two to four weeks. A 90-day supply is mailed directly to the prescriber's office or to the patient's address once approved. Hawaii residents on outer islands should confirm mailing logistics because some programs restrict delivery to a licensed pharmacy address [16].

The NeedyMeds database (needymeds.org) and RxAssist (rxassist.org) both maintain current program details and income cutoffs. Checking these resources directly is preferable to relying on cached program information, since Novo Nordisk adjusts income thresholds annually.

Telehealth Access to Liraglutide Prescriptions in Hawaii

Telehealth prescribing of liraglutide is fully legal in Hawaii. The state's telehealth laws, codified under Hawaii Revised Statutes Section 453-1.3, permit licensed physicians, advanced practice registered nurses (APRNs), and physician assistants (PAs) to prescribe controlled and non-controlled substances via synchronous audio-video encounters without requiring an in-person visit first [17].

The Ryan Haight Online Pharmacy Consumer Protection Act does not classify liraglutide as a controlled substance, so the prescribing rules that apply to buprenorphine or stimulants via telehealth do not apply here. A Hawaii-licensed provider can evaluate a patient via video call, confirm eligibility criteria (BMI <30 for weight management, or A1C above goal for diabetes), and send a prescription electronically to any Hawaii-licensed pharmacy or to a participating mail-order pharmacy the same day [17].

Several national telehealth platforms operate in Hawaii and can prescribe liraglutide or its GLP-1 alternatives: Ro, Hims and Hers, Found, and HealthRX itself. Patients on outer islands (Molokai, Lanai, the rural Hamakua Coast of the Big Island) benefit most from this pathway because specialist endocrinologists and obesity medicine physicians remain scarce outside Honolulu.

The Obesity Medicine Association's 2023 position statement endorses telehealth as an appropriate care delivery model for obesity pharmacotherapy, provided the provider conducts a comprehensive medical history review and assesses cardiovascular contraindications before initiating a GLP-1 agent [18].

Liraglutide Clinical Efficacy: What the Evidence Shows

SCALE Obesity (NCT01272219, N=3,731) demonstrated that liraglutide 3.0 mg daily produced a mean weight loss of 8.4 kg (8.4% body weight) at 56 weeks compared to 2.8 kg in the placebo group (P<0.001) [19]. The trial enrolled adults with a BMI of 30 or higher, or BMI of 27 or higher with dyslipidemia or hypertension, and all participants received diet and exercise counseling. The responder rate for at least 5% weight loss was 63.2% with liraglutide versus 27.1% with placebo [19].

The LEADER trial (N=9,340) assessed cardiovascular outcomes in patients with type 2 diabetes treated with liraglutide versus placebo over a median 3.8 years. Liraglutide reduced the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 13% relative to placebo (HR 0.87; 95% CI 0.78 to 0.97; P<0.001 for non-inferiority, P=0.01 for superiority) [20]. This cardiovascular benefit distinguishes liraglutide from older diabetes medications and provides a clinical rationale for prescribing it in Hawaii's high-risk Pacific Islander and Native Hawaiian populations, who carry disproportionate rates of type 2 diabetes and cardiovascular disease.

A 2022 Cochrane review of GLP-1 receptor agonists for type 2 diabetes (Zaccardi et al.) confirmed that liraglutide produced clinically meaningful A1C reductions averaging 1.0 to 1.5 percentage points versus placebo across randomized controlled trials, with a low risk of hypoglycemia when used without concomitant sulfonylurea or insulin [21].

The most common adverse effects are gastrointestinal: nausea (up to 38.3% of participants in SCALE Obesity), vomiting, diarrhea, and constipation [19]. These effects generally peak during the first four to eight weeks of dose escalation and attenuate over time. The FDA prescribing label carries a boxed warning for thyroid C-cell tumors observed in rodent studies; liraglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [1].

Practical Cost-Reduction Strategy for Hawaii Patients

The cheapest legal path to liraglutide in Hawaii depends on insurance status. Three tiers apply to most patients.

For commercially insured patients, verify Victoza or Saxenda formulary tier before the plan year starts. If covered, stack the Novo Nordisk savings card to bring the copay to $25 per month. Request a 90-day supply at mail-order rates, which typically reduce per-unit cost by 10 to 15% compared to 30-day retail fills [12].

For uninsured patients with income at or below 400% of the federal poverty level, apply for the Novo Nordisk PAP directly at novonordisk-us.com/patients/patient-assistance-program.html. Processing takes two to four weeks. While the application is pending, a short bridge supply of compounded liraglutide from a Hawaii-licensed 503A pharmacy at roughly $150 per month can maintain continuity of treatment [16].

For Med-QUEST patients with strong clinical documentation (A1C above 8.0%, documented cardiovascular disease, or BMI above 35 with comorbidities), file a PA request. If denied, escalate to a formal appeal and request a peer-to-peer review with the Medicaid medical director. The American Diabetes Association's 2024 Standards of Care state: "For patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, a GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended" [22]. Citing this guideline directly in the PA letter strengthens the clinical argument.

Switching to a lower-cost GLP-1 alternative is a fourth option worth discussing with a prescriber. Semaglutide (Ozempic for diabetes, Wegovy for weight management) is a once-weekly injection with comparable or superior efficacy data and, in some Hawaii plans, a more favorable formulary tier. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo [23]. A prescriber can compare the net cost for a given patient after savings cards and insurance negotiation before defaulting to liraglutide purely on familiarity.

Hawaii patients on the outer islands can use a telehealth visit with a HealthRX provider to get a prescription sent to a 503A compounding pharmacy with Hawaii delivery privileges, completing the entire process without a ferry ride or interisland flight.

Hawaii-Specific Considerations for Pacific Islander and Native Hawaiian Patients

Native Hawaiians and Pacific Islanders (NHPI) experience type 2 diabetes at more than twice the rate of non-Hispanic white adults in Hawaii, according to the Hawaii State Department of Health's 2022 chronic disease report [24]. Cardiovascular mortality rates in the NHPI population exceed national averages, making GLP-1 therapy both clinically appropriate and medically urgent for a large share of Hawaii's liraglutide-eligible population.

Cultural and geographic barriers compound cost barriers. Many Native Hawaiian families rely on Med-QUEST, which does not cover liraglutide. Rural communities on Molokai and in the Puna district of the Big Island have limited pharmacy access; compounded liraglutide shipped from a mainland 503A pharmacy with a Hawaii permit may be the only practical option. The University of Hawaii's Native Hawaiian Health Scholarship Program and the Papa Ola Lokahi network of Native Hawaiian health centers can serve as clinical entry points for patients who qualify for subsidized care [25].

Research published in Diabetes Care in 2021 found that GLP-1 receptor agonist therapy reduced cardiovascular event rates in Asian and Pacific Islander subgroups similarly to outcomes seen in the overall LEADER population, though subgroup sample sizes in individual trials remain smaller than ideal [26]. Extrapolating LEADER's HR of 0.87 to Hawaii's NHPI population is clinically reasonable given the consistency of GLP-1 mechanism across ethnicities.

Prescribers working with NHPI patients should review the FDA label for liraglutide's renal dosing notes: no dose adjustment is required for mild to moderate renal impairment, but liraglutide exposure increases in severe renal impairment and the drug is not recommended when eGFR falls below 15 mL/min/1.73 m2 [1].